MoonLake Immunotherapeutics MLTX shares are trading approximately 23% higher Tuesday morning on high volume.
MoonLake's average session volume over a 100-day period is about 158,900, according to data from Benzinga Pro. Tuesday's trading volume has already exceeded 113,400 at the time of publication.
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases
MLTX Price Action: MoonLake has traded between $4.25 and $15.19 over a 52-week period.
The stock was up 23% at $7.84 at press time.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.